MolMed S.p.A. | Balance Sheet

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
Cash & Short Term Investments
8,563.00
11,390.00
29,938.00
19,702.00
18,111.00
Total Accounts Receivable
6,012.00
5,891.00
8,987.00
10,010.00
6,431.00
Inventories
1,063.00
844.00
794.00
1,067.00
2,286.00
Other Current Assets
1,757.00
756.00
303.00
470.00
338.00
Total Current Assets
17,395.00
18,881.00
40,022.00
31,249.00
27,166.00
Net Property, Plant & Equipment
1,724.00
5,996.00
11,138.00
11,567.00
11,860.00
Total Investments and Advances
7.00
-
-
-
210.00
Long-Term Note Receivable
4,000.00
2,557.00
2,457.00
-
-
Intangible Assets
298.00
330.00
381.00
571.00
666.00
Other Assets
2,103.00
1,819.00
2,887.00
3,514.00
3,182.00
Total Assets
25,527.00
29,583.00
56,885.00
46,901.00
43,084.00
ST Debt & Current Portion LT Debt
3.00
-
-
-
-
Accounts Payable
9,480.00
9,852.00
13,559.00
12,526.00
8,542.00
Income Tax Payable
387.00
363.00
448.00
405.00
344.00
Other Current Liabilities
1,785.00
1,761.00
4,839.00
5,175.00
4,807.00
Total Current Liabilities
11,655.00
11,976.00
18,846.00
18,106.00
13,693.00
Long-Term Debt
1,032.00
-
-
-
-
Provision for Risks & Charges
184.00
208.00
197.00
146.00
147.00
Other Liabilities
2,523.00
5,317.00
5,913.00
6,500.00
4,611.00
Total Liabilities
15,394.00
17,501.00
24,956.00
24,752.00
18,451.00
Common Equity (Total)
10,133.00
12,082.00
31,929.00
22,149.00
24,633.00
Total Shareholders' Equity
10,133.00
12,082.00
31,929.00
22,149.00
24,633.00
Total Equity
10,133.00
12,082.00
31,929.00
22,149.00
24,633.00
Liabilities & Shareholders' Equity
25,527.00
29,583.00
56,885.00
46,901.00
43,084.00

About MolMed

View Profile
Address
Via Olgettina, 58
Milan Milan 20132
Italy
Employees -
Website http://www.molmed.it
Updated 09/14/2018
Molecular Medicine SpA is a medical biotechnology company which focuses on the research, development and clinical validation of therapies to treat cancer. The company's approach is based on finding drugs that target the reduction of tumor mass in the acute stage, as well as on the provision of selective therapies to eliminate the residual disease. Its pipeline includes antitumor therapeutics in clinical and preclinical development: Zalmoxis (TK) is a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immune-suppression.